Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
June 30, 2020
Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow’s Feet, Respectively
June 4, 2020
Revance to Participate in the 40th Annual William Blair Growth Stock Conference
June 2, 2020
Revance to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
June 1, 2020
Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®
May 19, 2020
Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices
May 7, 2020
Revance Reports First Quarter 2020 Financial Results, Provides Corporate Update
May 1, 2020
Revance and Mylan Biosimilar to BOTOX® Program Decision to Extend Beyond April 30, 2020
April 30, 2020
Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020
April 7, 2020
Revance to Participate in the 19th Annual Needham Virtual Healthcare Conference
March 26, 2020
Revance Provides Corporate Update in Light of COVID-19
Displaying 81 - 90 of 288